Study of combination therapy for advanced liver cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new combination of drugs (envafolimab, suvemcitug, and HAIC) to shrink advanced or unresectable liver cancer. It is for people who have not had systemic treatment before and have good organ function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage IV or stage III liver cancer that cannot be removed by surgery.
- You have not had any previous systemic anti-cancer treatment, including immunotherapy, targeted therapy, or herbal medicine.
- Your liver function is relatively good (Child-Pugh score of 7 or less).
- Your blood counts and kidney function are within acceptable ranges.
- You are between 18 and 75 years old.
- You are willing to use birth control during and for 6 months after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of liver-directed chemotherapy (HAIC), a targeted drug (lenvatinib), and an immunotherapy (envafolimab) to see if it can shrink liver cancers that are difficult to operate on. The goal is to make these cancers removable by surgery.
This trial tests a combination of immunotherapy (camrelizumab), a targeted drug (rivoceranib), and liver-directed chemotherapy (HAIC) to shrink liver tumors enough to make them removable with surgery. It is for people with intermediate or advanced liver cancer that has not spread outside the liver.
This trial tests a combination of four treatments (two immunotherapy drugs, a blood-vessel-blocking drug, and chemotherapy delivered directly to the liver) to shrink unresectable (inoperable) advanced liver cancer and potentially make it removable by surgery. The goal is to help patients who have never had cancer treatment before.
This trial tests a combination of treatments for people with liver cancer that can be surgically removed. The goal is to see if the combination helps shrink tumors and improve outcomes before surgery.
This trial tests a combination of liver-directed chemotherapy (HAIC), an immunotherapy drug (sintilimab), and a drug that blocks blood vessel growth (bevacizumab biosimilar) for advanced liver cancer that hasn't been treated with systemic therapy before. The goal is to see if this triple therapy can shrink or control the cancer.
This trial tests if combining three therapies (sintilimab, lenvatinib, and HAIC) before surgery can help shrink liver tumors that are on the borderline of being removable. It's for people whose cancer has spread into nearby blood vessels but not to other organs.
Hear when a new Potentially Resectable Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.